The Beginning of the Biosimilars Era in Multiple Sclerosis

home / roundtable-discussions / beginning-biosimilars-era-ms

Jeff Cohen, MD; Alycin Magruder, PharmD; and Sarah Anderson, PharmD, discuss the recent introduction of biosimilars into the therapeutic landscape of multiple sclerosis, and the downstream effects for physicians, patients, and payers in this new era of treatment.

Resources for Providers and Patients
Generic and Biosimilar Medications | National MS Society
Generic and Biosimilar FAQs
5 Things to Know About Biosimilars - Momentum Magazine
Ask an MS Expert: Biosimilars and Generics
Tyruko News Bulletin
Patient Assistance Program
Guide to Prescription Financial Assistance
© 2024 MJH Life Sciences

All rights reserved.